Bellinzona, May 15, 2020 – We are proud to announce the launch of the company website that provides most relevant information on the technology and pipeline of MV BioTherapeutics. We have changed the original name of the company from MicroVaccines to MV BioTherapeutics (from now on MV).
“During the past years we have developed therapeutic live biotherapeutics with different mode of action as compared to the original live attenuated microbial vaccines, which were exemplified as microvaccines” says Dr. Fabio Grassi, founder and Chairman of MV.
“With two lead indications and potential future developments of this promising application, it was important to characterize the company as non-exclusively dedicated to vaccines that is a very specific pharmaceutical area.”
The abbreviation MV is directly related to the two patented microorganisms ApyraMed® and ApyraVax®